Trial Profile
Phase III trial of eprotirome in patients with primary hyperlipidaemia with a high risk for cardiovascular disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2012
Price :
$35
*
At a glance
- Drugs Eprotirome (Primary)
- Indications Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- 14 Feb 2012 Status changed from planning to discontinued, according to a Karo Bio media release.
- 29 Apr 2011 New trial record